A potential ‘game changer’ for eye disease

By Jan Jarvis

katalin-prokai-tatrai
An eye drop that could prevent blindness caused by glaucoma is one step closer to becoming a reality.

A novel pharmacological intervention to control retinal ganglion cell death caused by glaucoma is in preclinical development, said Katalin Prokai-Tatrai, PhD, Associate Professor in the Center for Neuroscience Discovery and the Department of Pharmaceutical Sciences in the UNT System College of Pharmacy.

“We believe that this novel therapeutic intervention will be effective for other blinding eye diseases associated with neurodegeneration, such as age-related macular degeneration,” said Dr. Prokai-Tatrai. “We are very hopeful we will generate data that shows we can prevent and stop the damage that leads to blindness.

“If it works, it will be a game-changer in terms of how neurodegenerative eye diseases are treated.”

The five-year study is funded by a $2.1 million grant from the National Eye Institute at the National Institutes of Health.

Initially the study will target the effectiveness of the drug for glaucoma, the second-leading cause of blindness. The study will then be expanded to treat other neurodegenerative diseases impacting the brain.

“The beauty of our drug is that it remains inactive until it reaches the retina when applied in eye drops,” Dr. Prokai –Tatrai said.

Scientists know that glaucoma is caused by elevated pressure, but the mechanism behind it is not fully clear. Several possibilities are under investigation. Dr. Prokai-Tatrai said her translational research focuses on neuroprotection, not the mechanism that causes the elevated pressure.

“Our goal is to prevent neuron death using the eye drops, because once those neurons die they are gone forever,” she said. “Our preliminary data is unprecedented and very promising in terms of preserving visual acuity.

“This gives us hope, that if the approach is successful, we can develop a complementary therapy used together with conventional medications for those with glaucoma.”

The multidisciplinary research involves medicinal chemistry-driven drug discovery and delivery, retina proteomics and ophthalmology and is in collaboration with other researchers at UNTHSC and at the University of Missouri-Kansas City School of Medicine.

Recent News

Latino students posing in lab clothing.
  • On Campus
|Jun 1, 2023

HSC to host free Latinos en Medicina Camp

The University of North Texas Health Science Center at Fort Worth is hosting a free, weeklong Latinos en Medicina Camp for Fort Worth and Tarrant County children. The camp, which starts Monday and ends June 9, is for children ages 10-13 and aims to raise awareness about careers in health care in ...
Maria Crompton
  • Our People
|May 31, 2023

TCOM rural track graduate returns home to lead the ROME program

She’s back! Dr. Maria Crompton is the Texas College of Osteopathic Medicine’s new director of Rural Medical Education at The University of North Texas Health Science Center at Fort Worth. Crompton, a TCOM Rural Track graduate in 2008, has been a faculty member serving in both clinical and aca...
SHP Grads
  • Our People
|May 31, 2023

Highlighting high achievers of HSC’s Master of Science in Lifestyle Health Sciences and Coaching Program

The University of North Texas Health Science Center at Fort Worth’s commencement ceremony happened to land in the middle of National Lifestyle Medicine Week. HSC’s School of Health Professions Department of Personalized Health and Well-Being celebrated these two events by conferring the degrees ...
Ih D Conference Main
  • On Campus
|May 25, 2023

HSC’s Institute for Health Disparities to host ‘Engaging the Whole Person’ conference

The public is invited to learn more about whole health, including the actions and barriers to achieving health equity for minorities, at this year’s 18th Annual Texas Conference on Health Disparities at The University of North Texas Health Science Center at Fort Worth. “Engaging the Whole Per...